| Primary information |
|---|
| sequence ID | Seq_3172 |
| Peptide sequence | GSEMVVAGKLQDR |
| CancerPDF_ID | CancerPDF_ID803, CancerPDF_ID1856, CancerPDF_ID8577, CancerPDF_ID9820, CancerPDF_ID9821, |
| PMID | 19795908,21136997,23667664,21533267,21533267 |
| Protein Name | Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4,Inter-alpha-trypsin inhibitor heavy chain H4 |
| UniprotKB Entry Name | ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN,ITIH4_HUMAN |
| Fluid | Plasma,Serum,Serum,Serum,Serum |
| M/Z | "695.35, 463.90",1388.7082,1388.71,463.91,469.24 |
| Charge | "2, 3",1,1,3,3 |
| Mass (in Da) | NA,NA,1390.6,NA,NA |
| fdr | NA,NA,NA,NA,NA |
| Profiling Technique | LC-MS,LC-MS,MALDI-TOF,LC-MS,LC-MS |
| Peptide Identification technique | MALDI-TOF/TOF,LC-MS-MS/MS,FT-ICR MS/MS + nano-HPLC,LC/MS/MS,LC/MS/MS |
| Quantification Technique | LC-MRM (multiple reaction monitoring),LC-ESI-MS,NA,Multiple Reaction Monitoring,Multiple Reaction Monitoring |
| Labelled/Label Free | Labelled,Label Free,Label Free,Label Free,Label Free |
| FDR | less than 7%,NA,NA,1.49,1.49 |
| CancerPDF_ID | CancerPDF_ID803, CancerPDF_ID1856, CancerPDF_ID8577, CancerPDF_ID9820, CancerPDF_ID9821, |
| p-Value | NA,NA,NA,NA,NA |
| Software | FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT(v. 2.2.01),MASCOT,MASCOT,MASCOT |
| Length | 13,13,13,13,13 |
| Cancer Type | Ductal adenocarcinoma of the pancreas (DAP),Colorectal cancer,"Breast cancer, Lung cancer, Rectal cancer",Lung adenocarcinoma,Lung adenocarcinoma |
| Database | NCBI refseq Protein Database,SwissProt Database,NA,Swissprot Database (57.4),Swissprot Database (57.4) |
| Modification | NA,NA,NA,NA,Oxidation |
| Number of Patients | "42 normal, 28 patients",30 patients and 30 healthy controls,"Breast Cancer =84, lung cancer= 70, Rectal cancer = 30patients; 500 healthy",62 lung adenocarcinoma and 30 healthy control,62 lung adenocarcinoma and 30 healthy control |
| Regulation | NA,NA,NA,"Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal","Differentially expressed between earlier-stage lung cancer group (stage-I, II, and IIIa) vs normal" |
| Validation | NA,Leave One out Cross validation,NA,MRM-based validation of 19 candidates,MRM-based validation of 19 candidates |
| Sensitivity | NA,NA,NA,NA,NA |
| Specificity | NA,NA,NA,NA,NA |
| Accuracy | NA,NA,NA,NA,NA |
| Peptide Atlas | PeptideAtlas |
| IEDB | |